Work

Serotherapy with Alemtuzumab but Not ATG Is Associated with Increased Adenovirus Infection in Pediatric Recipients of Cord Blood Grafts

Year: 2015

Type: article

Abstract: Unrelated cord blood transplant (UCBT) is an established graft source for HSCT especially for minorities. Use of serotherapy such as anti-thymocyte globulin (ATG) and alemtuzumab is associated with delayed immune reconstitution, leading to increased viral reactivation especially when the donors are virus naïve. Therefore, we studied the impact of serotherapy along with other factors on viral reactivation (EBV, CMV, adenovirus (ADV)), GVHD, and transplant-related mortality (TRM) at 100 days in pediatric patients after UCBT.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2014.11.326

Authors: Ramona Chaudhry, Neha Joshi, Catherine M. Bollard, David A. Jacobsohn

Institutions: George Washington University, Children's National

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650